Carbon Biosciences

The company's proprietary platform focuses on leveraging novel parvoviruses, which are distinct from the commonly used adeno-associated viruses (AAVs) in gene therapy. This approach aims to address several key limitations of current gene therapy technologies. Carbon's vectors are designed to carry larger genetic payloads, target specific tissues with greater precision, and have minimal pre-existing neutralizing immunity in the population. This allows for the potential to re-dose patients, which is a significant challenge with AAV-based therapies due to the immune response they generate. A recent collaboration announced in June 2025 with WhiteLab Genomics aims to use artificial intelligence to further engineer Carbon's parvovirus capsids to optimize delivery to specific cell types and accelerate development.

Carbon Biosciences' business model is centered on developing a pipeline of gene therapy candidates for genetic diseases. Its initial lead program, CGT-001, targets cystic fibrosis (CF) and is designed to deliver the full-length CFTR gene, which is too large for conventional AAV vectors, specifically to lung tissue. The company's work in CF is supported by a collaborative agreement with the Cystic Fibrosis Foundation. Beyond CF, the company is expanding its pipeline to include treatments for pulmonary and cardiac diseases, utilizing its CBN-1000 and CBN-1100 capsids. The company plans to use its funding to advance these programs through IND-enabling studies.